Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Luminescent Wearable Sensor on Anions from Cotton Fabric Grafted with Cu-In-Zn-S Colloidal Quantum Dots.

Sensors (Basel, Switzerland)·2026

Same author

Advances in Quinazolinone-Based Tumor-Targeted Inhibitors.

Chemistry & biodiversity·2026

Same author

Drug-related pulmonary fibrosis: A real-world pharmacovigilance study of the FDA Adverse Event Reporting System.

Medicine·2026

Same author

An Intelligent Interactive Management Platform for Rheumatoid Arthritis Care: Real-World Observational Study.

JMIR medical informatics·2026

Same author

Mosaic Inverted Hemagglutinin Extracellular Vesicle Vaccines Elicit Protective Systemic and Mucosal Immunity against Heterosubtypic Influenza Infection.

ACS nano·2026

Same author

Regulating polysaccharide structure and bioactivity via free radical degradation: a review of mechanisms, effects, and application prospects.

Frontiers in nutrition·2026

Search research articles

Related Experiment Video

Updated: Jun 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Progress in small-molecule inhibitors targeting PD-L1.

Jindan Xu^1,2,3, Yuanfang Kong¹, Pengbo Zhu^1,2,3

¹Henan University of Chinese Medicine Zhengzhou 450046 Henan China tongyan1974@126.com arphylee@126.com chunhong_dong@hactcm.edu.cn.

RSC Medicinal Chemistry

|April 26, 2024

Summary

This summary is machine-generated.

Small-molecule inhibitors targeting programmed cell death-ligand 1 (PD-L1) offer an alternative to antibodies for cancer immunotherapy. This review summarizes recent advancements in small-molecule PD-L1 inhibitors, aiding future drug design.

More Related Videos

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Related Experiment Videos

Last Updated: Jun 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Area of Science:

Immunology
Pharmacology
Medicinal Chemistry

Background:

Programmed cell death-ligand 1 (PD-L1) is overexpressed in tumors, suppressing T-cell activity and hindering anti-cancer immune responses.
Monoclonal antibodies targeting PD-1/PD-L1 are effective cancer immunotherapies but have drawbacks like high cost and long half-life.
These limitations drive the development of small-molecule inhibitors for PD-1/PD-L1 interaction.

Purpose of the Study:

To elaborate on the structural characteristics of PD-L1 and its complexes with inhibitors.
To summarize small molecule inhibitors targeting PD-L1 developed over the last decade.
To provide insights for the future design and synthesis of novel small molecule PD-L1 inhibitors.

Main Methods:

Literature review of small molecule inhibitors targeting PD-L1.
Analysis of structural characteristics of PD-L1 and its complexes with inhibitors.
Summary of small molecule inhibitors developed in the past ten years.

Main Results:

Numerous small-molecule inhibitors targeting PD-L1 have been designed and synthesized.
Biphenyl core structures are prominent in many effective small-molecule inhibitors.
Research focus has shifted towards PD-L1 inhibitors over PD-1 inhibitors.

Conclusions:

Small-molecule inhibitors represent a promising therapeutic strategy in cancer immunotherapy.
Understanding PD-L1 structural features is crucial for rational drug design.
Further development of small molecule PD-L1 inhibitors holds potential for improved cancer treatment.